DEK regulates B-cell proliferative capacity and is associated with aggressive disease in low-grade B-cell lymphomas.

Authors: Hopper, Melissa A., Dropik, Abigail R., Walker, Janek S., Novak, Joseph P., Laverty, Miranda S., Manske, Michelle K., Wu, Xiaosheng, Wenzl, Kerstin, Krull, Jordan E., Sarangi, Vivekananda, Maurer, Matthew J., Yang, Zhi-Zhang, Del Busso, Miles D., Habermann, Thomas M., Link, Brian K., Rimsza, Lisa M., Witzig, Thomas E., Ansell, Stephen M., Cerhan, James R., Jevremovic, Dragan

Source: Blood Cancer Journal; 10/9/2024, Vol. 14 Issue 1, p1-10, 10p

Subject Terms: OVERALL survival, CELL lines, LYMPHOMAS, BIOMARKERS, VENETOCLAX

Aberrant activation of AXL may drive progression of squamous cell carcinoma in CLL patients: a mechanistic study with clinical implications.

Authors: Sinha, Sutapa, Guo, Ray, Del Busso, Miles D., Han, Weiguo, Boysen, Justin, Wellik, Linda E., Ghosh, Asish K., Kay, Neil E.

Source: British Journal of Cancer; Aug2024, Vol. 131 Issue 3, p589-600, 12p